Comparative Pharmacology
Head-to-head clinical analysis: SEROSTIM versus ZOMACTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEROSTIM versus ZOMACTON.
SEROSTIM vs ZOMACTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SEROSTIM is a recombinant human growth hormone that binds to growth hormone receptors, activating JAK2/STAT5 signaling pathways, leading to increased production of insulin-like growth factor 1 (IGF-1). It promotes linear growth, protein synthesis, and lipolysis.
ZOMACTON is a recombinant human growth hormone that binds to growth hormone receptors on cell surfaces, activating intracellular signaling cascades (primarily JAK-STAT pathway) leading to increased IGF-1 production, which mediates growth and metabolic effects including linear growth, protein synthesis, and lipolysis.
0.1 mg/kg subcutaneously once daily for 4 weeks; alternatively, 4 mg subcutaneously once daily for 4 weeks for patients ≥35 kg.
Intramuscular or subcutaneous injection: 0.1-0.3 mg/kg/day (up to 0.6 mg/kg/day) divided into 1-2 doses. Typical adult dose for growth hormone deficiency: 0.2 mg/kg/day subcutaneously.
None Documented
None Documented
Terminal half-life of approximately 2-3 hours after subcutaneous administration; prolonged in renal impairment (up to 6-8 hours).
Terminal elimination half-life: 2-3 hours after subcutaneous administration; clinically, this necessitates daily or more frequent dosing.
Primarily renal (90% metabolized in liver and kidneys; 0.1% excreted unchanged in urine); biliary/fecal negligible.
Renal: nearly 100% of absorbed dose, mostly as intact hormone; negligible biliary/fecal elimination.
Category C
Category C
Growth Hormone
Growth Hormone